Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-04-08
DOI
10.1111/bph.15850
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages
- (2022) Elaheh Abdollahi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- High glucose-induced effects on Na+-K+-Cl- cotransport and Na+/H+ exchange of blood-brain barrier endothelial cells: involvement of SGK1, PKCβII and SPAK/OSR1
- (2021) Nicholas R. Klug et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- SGLT2 Inhibitor–Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy—A Novel Hypothesis
- (2021) Sunder Mudaliar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Visualising and understanding cGMP signals in the cardiovascular system
- (2021) Robert Feil et al. BRITISH JOURNAL OF PHARMACOLOGY
- Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
- (2021) Sin-Hee Park et al. Cardiovascular Diabetology
- Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions
- (2021) Coert J Zuurbier et al. CARDIOVASCULAR RESEARCH
- Oxidative Stress and Hypertension
- (2021) Kathy K. Griendling et al. CIRCULATION RESEARCH
- Studying the Endothelial Glycocalyx in vitro: What Is Missing?
- (2021) Andrew B. Haymet et al. Frontiers in Cardiovascular Medicine
- THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
- (2021) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets
- (2021) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
- (2021) Maximilian Trum et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
- (2021) William Durante et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species
- (2021) Xiaoling Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells
- (2021) Laween Uthman et al. BIOMEDICINE & PHARMACOTHERAPY
- Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy
- (2021) Rosalinda Madonna et al. VASCULAR PHARMACOLOGY
- Targeting the NLRP3 inflammasome in cardiovascular diseases
- (2021) Stefano Toldo et al. PHARMACOLOGY & THERAPEUTICS
- Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
- (2020) Kevin Damman et al. EUROPEAN JOURNAL OF HEART FAILURE
- Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress
- (2020) Panagiota Efstathia Nikolaou et al. ANTIOXIDANTS & REDOX SIGNALING
- Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
- (2020) Detmar Kolijn et al. CARDIOVASCULAR RESEARCH
- Basic Mechanisms of Diabetic Heart Disease
- (2020) Rebecca H. Ritchie et al. CIRCULATION RESEARCH
- Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
- (2020) Byambasuren Ganbaatar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Regulation of Vascular Function and Inflammation via Cross Talk of Reactive Oxygen and Nitrogen Species from Mitochondria or NADPH Oxidase—Implications for Diabetes Progression
- (2020) Andreas Daiber et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
- (2020) Atsushi Kuno et al. Scientific Reports
- Basic and Therapeutic Aspects of Angiogenesis Updated
- (2020) Guy Eelen et al. CIRCULATION RESEARCH
- Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
- (2020) Donato Cappetta et al. PHARMACOLOGICAL RESEARCH
- Molecular, Cellular, and Clinical Evidence That Sodium‐Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure
- (2020) Milton Packer Journal of the American Heart Association
- Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies
- (2020) Afnan S. Alshnbari et al. Diabetes Therapy
- Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
- (2020) Laween Uthman et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cells of the adult human heart
- (2020) Monika Litviňuková et al. NATURE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- NLRP3 inflammasome in endothelial dysfunction
- (2020) Baochen Bai et al. Cell Death & Disease
- Human Nitric Oxide Synthase—Its Functions, Polymorphisms, and Inhibitors in the Context of Inflammation, Diabetes and Cardiovascular Diseases
- (2020) Magdalena Król et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
- (2020) Rio P. Juni et al. KIDNEY INTERNATIONAL
- VEGF in Signaling and Disease: Beyond Discovery and Development
- (2019) Rajendra S. Apte et al. CELL
- Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescence
- (2019) Sonia Khemais‐Benkhiat et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
- (2019) Alex Ali Sayour et al. Journal of Translational Medicine
- Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
- (2019) Scott Cooper et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
- (2019) Ghazaleh Behnammanesh et al. Frontiers in Pharmacology
- Endothelial function and dysfunction in the cardiovascular system: the long non-coding road
- (2019) João P Monteiro et al. CARDIOVASCULAR RESEARCH
- SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice
- (2019) Rebeca Ortega et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Co‐morbidities and co‐medications as confounders of cardioprotection ‐ does it matter in the clinical setting?
- (2019) Petra Kleinbongard et al. BRITISH JOURNAL OF PHARMACOLOGY
- Vascular Endothelial Cell Biology: An Update
- (2019) Krüger-Genge et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies
- (2019) Anandita Umapathy et al. ANGIOGENESIS
- Reactive Oxygen Species in Metabolic and Inflammatory Signaling
- (2018) Steven J. Forrester et al. CIRCULATION RESEARCH
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2018) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Hypertension with diabetes mellitus: physiology and pathology
- (2018) Mitsuru Ohishi HYPERTENSION RESEARCH
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity
- (2018) Biplab Giri et al. BIOMEDICINE & PHARMACOTHERAPY
- Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF
- (2018) Sanjiv J Shah et al. EUROPEAN HEART JOURNAL
- Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
- (2018) Luigi Ferrucci et al. Nature Reviews Cardiology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis
- (2018) Ting Yuan et al. Redox Biology
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
- (2017) Kosuke Kaji et al. INTERNATIONAL JOURNAL OF CANCER
- Diabetes and Wound Angiogenesis
- (2017) Uzoagu Okonkwo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of moesin, Src, and ROS in advanced glycation end product-induced vascular endothelial dysfunction
- (2017) Wei-jin Zhang et al. MICROCIRCULATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macro- and microvascular endothelial dysfunction in diabetes
- (2017) Yi Shi et al. Journal of Diabetes
- Effects of shear stress on endothelial cells: go with the flow
- (2016) D. A. Chistiakov et al. Acta Physiologica
- Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants
- (2016) Damayanthi Devineni et al. CLINICAL THERAPEUTICS
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
- (2016) Brian Tomlinson et al. Expert Opinion on Drug Metabolism & Toxicology
- Differential Roles of Protein Complexes NOX1-NOXO1 and NOX2-p47phox in Mediating Endothelial Redox Responses to Oscillatory and Unidirectional Laminar Shear Stress
- (2016) Kin Lung Siu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice
- (2016) Weiling Leng et al. MEDIATORS OF INFLAMMATION
- The Role of AGE/RAGE Signaling in Diabetes-Mediated Vascular Calcification
- (2016) Amber M. Kay et al. Journal of Diabetes Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started